Skip To Main Content
Lizzie Appleton on Muck Rack

Lizzie Appleton

As seen in: BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Lizzie Appleton’s profile

Articles by Lizzie Appleton

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling.

|
By Edward Armstrong, Shane Foo, Lizzie Appleton, Matthew K.L. Chiu
| BioRxiv
Abstract Abstract Background: Over the past decade, cancer immunotherapies have revolutionised the treatment of melanoma; however, responses vary across patient populations. Recently, baseline tumour size has been identified as an independent prognostic factor for overall survival in melanoma patients receiving immune checkpoint inhibitors (ICIs). MG1 is a novel oncolytic agent with broad tumour tropism that has recently entered early phase clinical trials.
Open in Who Shared Issue with article?

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma

|
By Victoria Jennings, Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton
| bmj.com
Oncolytic Virotherapy Melanoma Immunomodulation T-Lymphocytes Background Treatment for advanced melanoma has dramatically improved over recent years with the introduction of immunotherapy (particularly immune checkpoint inhibitor (ICI) antibodies against PD-1, PDL-1 and CTLA-4), and drugs targeting the MAPK/ERK signaling pathway (BRAF and MEK inhibitors).1 However, a significant number of patients do not respond to these interventions, due to the lack of targetable gene mutations (only...
Open in Who Shared Issue with article?
Show More